|
Shield Therapeutics PLC on Thursday highlighted a record performance from Accrufer, which it said helped drive a strong rise in annual sales. The Newcastle, England-based commercial-stage pharmaceutical company said its pretax loss narrowed to $17.1 million in 2025 from $26.6 million the year prior. Revenue jumped to $49.7 million from $32.2 million, while selling, general and administrative expenses fell to $31.6 million from $36.0 million. The latter primarily reflected a restructuring of the sales force announced in the fourth quarter of 2024. Revenue for Accrufer in the US grew 56% on-year, contributing around $46 million to the total 2025 sales. Shield Therapeutics said 2025 represents the strongest year on record for Accrufer, its oral iron medication used to treat iron deficiency, with record prescription volumes, increased average net selling prices, and record revenues. The average net selling price of Accrufer grew 21% on-year to $223 driven primarily by a reduction in the consignment business from 35% in 2024 to 22% in 2025 of the total prescriptions dispensed. The firm also noted a key milestone was achieved in the fourth quarter, with the company reaching cash flow positivity, ‘providing increased strategic and financial flexibility.’ As of the end of December, cash stood at $11.6 million, up from $6.5 million the year prior. Looking ahead, Shield Therapeutics said Accrufer is poised for a ‘transformative’ 2026. ‘We anticipate strong growth in 2026, driven by its existing sales force, marketing programs, and improved patient access - with the usual seasonal patterns expected to continue,’ the firm said. Shares in Shield Therapeutics were up 1.4% at 8.82 pence each in London on Thursday. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
